In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
The settlement provides Mylan with global licenses for its trastuzumab product.